Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Musashi 2 mRNA Expression in the Course of CML.

Sylvie Nadvornikova, Marketa Zackova, Tereza Lopotova, Hana Klamova, Jana Moravcova

Blood (2012) 120 (21): 2552.

https://doi.org/10.1182/blood.V120.21.2552.2552

Published: 2012

Journal Articles

HSP90 Chaperone – An Important Player in CML: Study At RNA and Protein Level

Marketa Zackova, Tereza Lopotova, Sylvie Nadvornikova, Hana Klamova, Jana Moravcova

Blood (2011) 118 (21): 4878.

https://doi.org/10.1182/blood.V118.21.4878.4878

Published: 2011

Journal Articles

Supportive Methods for Testing CML Progression in Addition to BCR-ABL Transcript Monitoring – What to Do If BCR-ABL Monitoring doesn't Work?

Tereza Lopotova, Marketa Zackova, Sylvie Nadvornikova, Hana Klamova, Jana Moravcova

Blood (2011) 118 (21): 4902.

https://doi.org/10.1182/blood.V118.21.4902.4902

Published: 2011

Journal Articles

Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders.

Katerina Machova Polakova, Sylvie Nadvornikova, Karla Zemanova, Hana Klamova, Tomas Jurcek, Dana Dvorakova, Daniela Zackova, Jiri Mayer, Marek Trneny, Jana Moravcova

Blood (2010) 116 (21): 3419.

https://doi.org/10.1182/blood.V116.21.3419.3419

Published: 2010

Journal Articles

Detection of BCR-ABL Mutation by High Resolution Melting Analysis Is Affected by the Sequence Content, Position and Type of Nucleotide Change and DNA Dye Together with Salt Composition of PCR Mixes.

Sylvie Nadvornikova, Vaclava Polivkova, Gouse M Shaik, Petr Draber, Jana Moravcova, Katerina Machova Polakova

Blood (2009) 114 (22): 1565.

https://doi.org/10.1182/blood.V114.22.1565.1565

Published: 2009

NARROW

The Musashi 2 mRNA Expression in the Course of CML.

HSP90 Chaperone – An Important Player in CML: Study At RNA and Protein Level

Supportive Methods for Testing CML Progression in Addition to BCR-ABL Transcript Monitoring – What to Do If BCR-ABL Monitoring doesn't Work?

Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders.

Detection of BCR-ABL Mutation by High Resolution Melting Analysis Is Affected by the Sequence Content, Position and Type of Nucleotide Change and DNA Dye Together with Salt Composition of PCR Mixes.

Email alerts

ASH Publications

American Society of Hematology

The Musashi 2 mRNA Expression in the Course of CML.

HSP90 Chaperone – An Important Player in CML: Study At RNA and Protein Level

Supportive Methods for Testing CML Progression in Addition to BCR-ABL Transcript Monitoring – What to Do If BCR-ABL Monitoring doesn't Work?

Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders.

Detection of BCR-ABL Mutation by High Resolution Melting Analysis Is Affected by the Sequence Content, Position and Type of Nucleotide Change and DNA Dye Together with Salt Composition of PCR Mixes.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only